Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SBTX · Entity 883 | Director | June 10, 2022 | June 13, 2022 |
| CARLSMED, INC.CARL · Entity 5551 | Director | June 03, 2026 | June 22, 2026 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | June 05, 2026 | July 17, 2026 |
| Omada Health, Inc.OMDA · Entity 2364 | Director | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 10, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09 | Direct | 18,000 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
CARLSMED, INC.
Report date June 03, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 497,697 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 13,698 · Balance 497,697 F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 4,305,806 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,305,806 F2: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 218,524 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 218,524 F3: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,117,743 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,117,743 F4: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
F2: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII").
F3: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A").
F4: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A").
F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein.
Edgewise Therapeutics, Inc.
Report date June 05, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05 | Direct | 16,377 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders.
Omada Health, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 192,571 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 694 · Balance 192,571 F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BOX INC
Report date June 02, 2017 · Filed June 08, 2017 · Amendment
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, LIDDLE DAVID E, Matteucci Paul A, Tansey Casey M, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Last balance in matching sequence
After 2017-06-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2: Prorata distribution in kind from the partnership without consideration to its limited partners. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectDirectly owned by USVP IX | 3,713,775 |
Reported balance
After 2017-06-02 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F2: Prorata distribution in kind from the partnership without consideration to its limited partners.
F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
INTERMOLECULAR INC
Report date November 08, 2018 · Filed November 13, 2018
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, Tansey Casey M, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2018-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Reported balance
After 2018-11-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-08 · Other · Disposed 4,280,779 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 856,155 |
Reported balance
After 2018-11-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-08 · Other · Acquired 856,155 · Balance 856,155 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-08 · Other · Disposed 856,155 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Steven Krausz | 97,593 |
Last balance in matching sequence
After 2018-11-13 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 4 · 2018-11-08 · Other · Acquired 102,093 · Balance 102,093 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 5 · 2018-11-12 · Sale · Disposed 2,100 · Balance 99,993 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 6 · 2018-11-13 · Sale · Disposed 2,400 · Balance 97,593 F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by David Liddle | 69,609 |
Reported balance
After 2018-11-08 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-08 · Other · Acquired 69,609 · Balance 69,609 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Paul Matteucci | 60,408 |
Reported balance
After 2018-11-08 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2018-11-08 · Other · Acquired 60,408 · Balance 60,408 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Jonathan Root | 85,851 |
Reported balance
After 2018-11-08 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2018-11-08 · Other · Acquired 85,851 · Balance 85,851 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Casey Tansey | 60,336 |
Reported balance
After 2018-11-08 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2018-11-08 · Other · Acquired 60,336 · Balance 60,336 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Philip Young | 82,370 |
Reported balance
After 2018-11-08 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2018-11-08 · Other · Acquired 82,370 · Balance 82,370 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 541,149 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectDirectly Owned by Spouse | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-19 · Other · Disposed 335 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Inspire Medical Systems, Inc.
Report date November 08, 2018 · Filed November 14, 2018
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2018-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 1,084,127 |
Reported balance
After 2018-11-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-08 · Other · Disposed 1,084,127 · Balance 1,084,127 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 216,825 |
Reported balance
After 2018-11-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-08 · Other · Acquired 216,825 · Balance 216,825 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-08 · Other · Disposed 216,825 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Irwin Federman | 18,212 |
Reported balance
After 2018-11-08 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Steven Krausz | 22,573 |
Reported balance
After 2018-11-08 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-11-08 · Other · Acquired 22,573 · Balance 22,573 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by David Liddle | 15,391 |
Reported balance
After 2018-11-08 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2018-11-08 · Other · Acquired 15,391 · Balance 15,391 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Paul Matteucci | 13,356 |
Reported balance
After 2018-11-08 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-08 · Other · Acquired 13,356 · Balance 13,356 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Jonathan Root | 18,982 |
Reported balance
After 2018-11-08 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2018-11-08 · Other · Acquired 18,982 · Balance 18,982 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Philip Young | 18,212 |
Reported balance
After 2018-11-08 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
OncoMed Pharmaceuticals Inc
Report date April 23, 2019 · Filed April 23, 2019
Section 16 reporting ended · disclosed 2019-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-04-23 transaction · row 1
1 source rowRow 1 · 2019-04-23 · Other · Disposed 121,020 · Balance 0 F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own.
F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.
eFFECTOR Therapeutics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, Tansey Casey M
Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 3,981,940 |
Last balance in matching sequence
After 2022-08-03 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 127,569 |
Last balance in matching sequence
After 2022-08-03 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:17 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 694 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000431 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,571 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| July 05, 2026 Filed Jul 7, 2026 23:24 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000323 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,877 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:23 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 10,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000252 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,057 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs will fully vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, subject to continued service through such vesting date. Read SEC document |
| June 05, 2026 Filed Jul 17, 2026 20:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001710072-26-000001 · primary_doc.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 22, 2026 10:02 UTC | CARLSMED, INC. CARL · Entity 5551 | GrantCommon Stock | 13,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-276601 · ownership.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,697 F1 · shares: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. Read SEC document |
| April 05, 2026 Filed Apr 7, 2026 20:06 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 882 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000142 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,175 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 22:37 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 915 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000006 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,293 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 22:56 UTC | Omada Health, Inc. OMDA · Entity 2364 | OtherCommon Stock | 146,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000406 · form4.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), without additional consideration, to its partners. F3 · ownership.nature: Shares held by USVP X Affiliates, L.P. F4 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of the USVP X Funds, has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 22:56 UTC | Omada Health, Inc. OMDA · Entity 2364 | OtherCommon Stock | 4,571,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000406 · form4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), without additional consideration, to its partners. F2 · ownership.nature: Shares held by U.S. Venture Partners X, L.P. F4 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of the USVP X Funds, has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 22:56 UTC | Omada Health, Inc. OMDA · Entity 2364 | OtherCommon Stock | 167,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000406 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,378 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), without additional consideration, to its partners. Read SEC document |
| October 05, 2025 Filed Oct 7, 2025 20:42 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 657 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-044515 · wk-form4_1759869756.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,630 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries C Preferred Stock · Derivative | 1,117,743 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · derivative · entry 16 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,117,743 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F5 · ownership.nature: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries C Preferred Stock · Derivative | 26,993 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · derivative · entry 15 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 26,993 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F4 · ownership.nature: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries B Preferred Stock · Derivative | 41,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · derivative · entry 14 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 41,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F4 · ownership.nature: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries A Preferred Stock · Derivative | 149,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · derivative · entry 13 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 149,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F4 · ownership.nature: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries C Preferred Stock · Derivative | 531,877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · derivative · entry 12 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 531,877 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F3 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries B Preferred Stock · Derivative | 825,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · derivative · entry 11 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 825,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F3 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionSeries A Preferred Stock · Derivative | 2,948,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · derivative · entry 10 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,948,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.exercise_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F7 · derivative.expiration_date: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F3 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | PurchaseCommon Stock | 466,666 | $15.00 | $6,999,990.00 |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 9 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483,999 F8 · shares: Includes 466,666 shares of the Issuer's common stock purchased by the Reporting Person in the Issuer's initial public offering at the public offering price of $15.00 per share. The purchase was made directly from the underwriters in connection with the offering. F9 · balance_after: Includes (i) 466,666 shares of the Issuer's common stock purchased by the reporting person in the Issuer's initial public offering at the public offering price of $15.00 per share, and (ii) 17,333 unvested RSUs convertible into approximately 17,333 shares of the Issuer's common stock. The RSUs will vest in equal annual installments over three years. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 1,117,743 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 8 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,117,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F5 · ownership.nature: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 26,993 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 7 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 218,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F4 · ownership.nature: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 41,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 6 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 191,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F4 · ownership.nature: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 149,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 149,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F4 · ownership.nature: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 531,877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,305,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F3 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 825,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,773,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F3 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | ConversionCommon Stock | 2,948,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,948,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: These securities were previously reported on a Form 3 filed by the Reporting Person as preferred stock of the Issuer. Each share of preferred stock of the Issuer converted into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering on a 1-to-1 basis without payment of additional consideration. The preferred stock has no expiration date. F3 · ownership.nature: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F6 · ownership.nature: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. Read SEC document |
| July 22, 2025 Filed Jul 25, 2025 00:27 UTC | CARLSMED, INC. CARL · Entity 5551 | GrantCommon Stock | 17,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-098529 · ownership.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,333 F1 · shares: Constitute an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in equal annual installments over three years. F2 · shares: Includes 17,333 unvested restricted stock units convertible into approximately 17,333 shares of the Issuer's common stock. F1 · balance_after: Constitute an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in equal annual installments over three years. F2 · balance_after: Includes 17,333 unvested restricted stock units convertible into approximately 17,333 shares of the Issuer's common stock. Read SEC document |
| July 05, 2025 Filed Jul 8, 2025 20:15 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000278 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,973 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 23:36 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.68 | $0.00 |
DisclosureSEC source: 0001562180-25-004957 · primarydocument.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 16, 2025 will become vested on the earlier of (i) June 16, 2026 or (ii) the business day prior to the 2026 annual meeting of stockholders. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries D Preferred Stock · Derivative | 10,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 13 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 10,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F4 · ownership.nature: Shares held by USVP X Affiliates, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries C-1 Preferred Stock · Derivative | 8,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 12 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 8,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F4 · ownership.nature: Shares held by USVP X Affiliates, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries C Preferred Stock · Derivative | 11,434 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 11 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 11,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F4 · ownership.nature: Shares held by USVP X Affiliates, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries B Preferred Stock · Derivative | 56,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 10 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 56,786 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F4 · ownership.nature: Shares held by USVP X Affiliates, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries A Preferred Stock · Derivative | 58,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 9 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 58,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F4 · ownership.nature: Shares held by USVP X Affiliates, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries D Preferred Stock · Derivative | 334,151 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 8 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 334,151 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F3 · ownership.nature: Shares held by U.S. Venture Partners X, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries C-1 Preferred Stock · Derivative | 258,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 7 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 258,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F3 · ownership.nature: Shares held by U.S. Venture Partners X, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries C Preferred Stock · Derivative | 357,402 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 6 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 357,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F3 · ownership.nature: Shares held by U.S. Venture Partners X, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries B Preferred Stock · Derivative | 1,775,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,775,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F3 · ownership.nature: Shares held by U.S. Venture Partners X, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionSeries A Preferred Stock · Derivative | 1,813,927 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · derivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,813,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F3 · ownership.nature: Shares held by U.S. Venture Partners X, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionCommon Stock | 145,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 146,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F4 · ownership.nature: Shares held by USVP X Affiliates, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 09, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | ConversionCommon Stock | 4,539,436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,571,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.33333 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported in Table II above on an as-converted basis and have no expiration date. F3 · ownership.nature: Shares held by U.S. Venture Partners X, L.P. F5 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X, and may be deemed to share voting and dispositive power over the shares held by the USVP X Funds. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:20 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 9,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000185 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,736 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs will fully vest on the first anniversary of June 5, 2025. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:14 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005749 · form4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Directly Owned by Spouse Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:14 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 541,149 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005749 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2 · shares: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 23:22 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 20,594 | $0.00 Strike: $17.13 | $0.00 |
DisclosureSEC source: 0001562180-24-005017 · primarydocument.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,594 Underlying: Common Stock · 20,594 shares Expires 2034-06-10 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 10, 2024 will become vested on the earlier of (i) June 10, 2025 or (ii) the business day prior to the date of the 2025 annual meeting of stockholders. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 20:56 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 4,126 | $42.41 | $174,983.66 |
DisclosureSEC source: 0001127602-24-013476 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 541,149 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document |
| April 24, 2024 Filed May 31, 2024 20:58 UTC Amendment | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 4,126 | $42.41 | $174,983.66 |
DisclosureSEC source: 0001127602-24-017132 · form4a.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 541,149 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 23:29 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 22,123 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001562180-23-005176 · primarydocument.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,123 Underlying: Common Stock · 22,123 shares Expires 2033-06-12 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders. Read SEC document |
| May 27, 2023 Filed May 30, 2023 20:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionRestricted Stock Unit · Derivative | 2,982 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017039 · form4.xml · derivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs") which represent a contingent right to receive one share of common stock for each RSU. 1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") which represent a contingent right to receive one share of common stock for each RSU. 1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs") which represent a contingent right to receive one share of common stock for each RSU. 1/3 of the RSUs vested on May 27,2021, and the remaining RSUs will vest annually thereafter over the next two years. Read SEC document |
| May 27, 2023 Filed May 30, 2023 20:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | Exercise / conversionCommon Stock | 2,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017039 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.